Bio-Europe

Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.

Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.

Selwyn Ho, CEO of Medigene, discusses the company’s pipeline strategy and upcoming milestones for its immuno-oncology platform.